Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Breast 11Other hematologic neoplasm 3Tumor-Agnostic 2Thoracic 2Lymphoid 2Head & Neck 2Gynecologic 2Sarcoma 1Plasma cell 1Dermatologic 1

Conditions

Keratosis, Actinic 1Disease 1

Interventions

pembrolizumab 161Nivolumab 133Ipilimumab 78Cyclophosphamide 47Specimen Handling 42Magnetic Resonance Spectroscopy 38cemiplimab 35Biopsy 31fludarabine 28trametinib 24relatlimab 24binimetinib 23Interleukin-2 22fludarabine phosphate 20dabrafenib 20atezolizumab 19Opdualag 19CTLA-4 Antigen 19aldesleukin 18Radiotherapy 18Radiosurgery 18encorafenib 17Blood Specimen Collection 17avelumab 14Immunoglobulin G 14Disulfides 13lifileucel 11lenvatinib 11Paclitaxel 11Bevacizumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Control Groups × Dermatologic × 1 year × Clear all
NCT07335003 2026-01-12

Study of the Photoprotection and Prevention of Actinic Damage With Anthelios Fluide 100 KA+ UVMune 400 in Patients With Multiple Actinic Keratoses

Cosmetique Active International

Phase NA Recruiting
80 enrolled
Dermatologic

Disease, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡